Reuters
09 Jul 2026, 04:54 UTC · 2h ago
Dr Reddy's delays semaglutide supply due to active ingredient issue
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
09 Jul 2026, 04:54 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Dr Reddy's Laboratories is delaying commercial supplies of semaglutide. — Delaying a high-demand GLP-1 drug directly impacts projected revenue and market share in a high-growth therapeutic area.
-0.70The supply delay is caused by an issue related to the active pharmaceutical ingredient (API). — An API issue suggests a technical or quality control failure that may take time to resolve.
-0.40Dr Reddy's shares declined following the announcement. — Reflects immediate investor sentiment and a negative price adjustment based on the news.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is delaying commercial supplies of semaglutide due to API issues, causing shares to decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1h ago
